Johnson & Johnson
$668.25B- Market cap
- $640.02B
- Debt
- +$47.94B
- Cash
- −$19.71B
Capital structure 93% equity / 7% debt · EV / Revenue 7.09x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $640.02B · View financials
Snapshot Sep 11, 2026, 4:00 PM ET
FY 2026 · Mkt cap
Decision snapshot: JNJ stock price at discount vs NVDA $265.58 current versus $419.82 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at NVDA's multiple
Implied fair value · at JNJ's multiple
Close Dec 31, 2025
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Multiple discount
Lower P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Ten period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 93% equity / 7% debt · EV / Revenue 7.09x
Capital structure 100% equity / 0% debt · EV / Revenue 20.80x · EV proxy / EBITDA proxy 33.72x
NVDA carries the larger enterprise value at $4.49T against $668.25B; JNJ trades on the lower EV / Revenue multiple (7.09x vs 20.80x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Johnson & Johnson · implied price per share
Bear
$93.96
Base
$115.89
Bull
$146.14
NVIDIA CORP · implied price per share
Bear
$43.09
Base
$52.57
Bull
$59.95
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Pfizer Inc.
JNJ vs PFE
Eli Lilly and Company
JNJ vs LLY
Abbott Laboratories
JNJ vs ABT
Amgen Inc.
JNJ vs AMGN
ADVANCED MICRO DEVICES INC
JNJ vs AMD
INTEL CORP
JNJ vs INTC
TEXAS INSTRUMENTS INC
JNJ vs TXN
Broadcom Inc.
JNJ vs AVGO
QUALCOMM INC/DE
JNJ vs QCOM
MICROCHIP TECHNOLOGY INC
JNJ vs MCHP
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.